What are the limitations of current studies on cannabis and PMR?

PostedFebruary 23, 2026

UpdatedFebruary 23, 2026

ByMy Patient Advice

Author: Julia Sutton, MSc | Reviewed by: Dr. Clarissa Morton, PharmD

While interest in cannabis for polymyalgia rheumatica is growing, the body of research remains limited. Understanding the limitations of cannabis research for PMR is crucial for interpreting findings and guiding future studies.

Key Study Constraints

Several factors contribute to the challenges in evaluating cannabis for PMR. Recognising these limitations helps researchers design more robust investigations.

Study Design Issues

Study design issues such as lack of randomisation, absence of control groups, and short follow-up periods reduce the reliability of current research. These design flaws make it difficult to draw definitive conclusions about cannabis effectiveness.

Sample Size

Small sample size in many studies limits statistical power. With few participants, results may not accurately represent the broader PMR population, making generalisation problematic.

Evidence Gaps in PMR Research

Evidence gaps in PMR research remain significant. Many studies focus on symptom relief without exploring long-term safety, optimal dosing, or interactions with other medications, leaving unanswered questions for clinical practice.

The limitations of cannabis research for PMR, including study design issues, sample size, and evidence gaps in PMR research, highlight the need for larger, well-controlled studies. Addressing these constraints will provide more reliable data to guide the safe and effective use of cannabis in managing PMR.

If you’re exploring cannabis treatment options for polymyalgia rheumatica, visit providers like LeafEase for personalised consultations and guidance tailored to your needs.

For a deeper dive into the science, diagnosis, and full treatment landscape, read our complete guide to Medical Cannabis and polymyalgia rheumatica.

Julia Sutton, MSc

Author

Julia Sutton is a clinical psychologist with a Master’s in Clinical Psychology and experience providing psychological assessment and therapy to adolescents and adults. Skilled in CBT, client-centered therapy, and evidence-based interventions, she has worked with conditions including depression, anxiety, bipolar disorder, and conversion disorder. She also has experience in child psychology, conducting psycho-educational evaluations and developing tailored treatment plans to improve learning and well-being.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the author's privacy.

Dr. Clarissa Morton, PharmD

Reviewer

Dr. Clarissa Morton is a licensed pharmacist with a Doctor of Pharmacy degree and experience across hospital, community, and industrial pharmacy. She has worked in emergency, outpatient, and inpatient pharmacy settings, providing patient counseling, dispensing medications, and ensuring regulatory compliance. Alongside her pharmacy expertise, she has worked as a Support Plan & Risk Assessment (SPRA) officer and in medical coding, applying knowledge of medical terminology, EMIS, and SystmOne software to deliver accurate, compliant healthcare documentation. Her skills span medication safety, regulatory standards, healthcare data management, and statistical reporting.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the reviewers's privacy.